We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

64 hedge funds and large institutions have $244M invested in Cymabay Therapeutics in 2017 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 22 increasing their positions, 6 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more capital invested

Capital invested by funds: $65M → $244M (+$179M)

267% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 6

250% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 10

219% more call options, than puts

Call options by funds: $402K | Put options by funds: $126K

64% more funds holding

Funds holding: 39 → 64 (+25)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
64
Holders Change
+25
Holders Change %
+64.1%
% of All Funds
1.6%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
35
Increased
22
Reduced
6
Closed
10
Calls
$402K
Puts
$126K
Net Calls
+$276K
Net Calls Change
+$247K

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$15.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$15.7M
3
BBA
Baker Bros. Advisors
New York
+$11.5M
4
RG
Redmile Group
California
+$11.1M
5
Franklin Resources
Franklin Resources
California
+$10.1M

Top Sellers

Rank Fund Capital Flow
1
GTC
Ghost Tree Capital
New York
-$3.74M
2
JGC
J. Goldman & Co
New York
-$1.73M
3
A
Abingworth
United Kingdom
-$387K
4
MWNA
Marshall Wace North America
New York
-$242K
5
ACI
Alpha Cubed Investments
California
-$115K
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$24.8M +$8.35M +1,234,956 +67%
BBA
2
Baker Bros. Advisors
New York
$24.1M +$11.5M +1,700,000 +132%
PA
3
Perceptive Advisors
New York
$18.9M +$15.9M +2,350,882 New
Fidelity Investments
4
Fidelity Investments
Massachusetts
$18.8M +$15.7M +2,327,520 New
Millennium Management
5
Millennium Management
New York
$13.7M +$8.64M +1,277,226 +300%
RG
6
Redmile Group
California
$13.3M +$11.1M +1,647,100 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$12.4M +$3.72M +549,569 +55%
A
8
Abingworth
United Kingdom
$12.4M -$387K -57,278 -4%
Franklin Resources
9
Franklin Resources
California
$12.1M +$10.1M +1,500,000 New
VVM
10
Versant Venture Management
California
$8.26M – – –
BC
11
Boxer Capital
California
$8.16M +$3.98M +587,986 +138%
OM
12
Opaleye Management
Massachusetts
$5.36M +$4.5M +665,000 New
Citadel Advisors
13
Citadel Advisors
Florida
$5.16M +$4.33M +640,027 New
BlackRock
14
BlackRock
New York
$4.94M +$2.92M +431,896 +238%
FCMI
15
Foresite Capital Management III
California
$4.84M +$4.06M +600,000 New
EI
16
EAM Investors
California
$4.79M +$4.02M +594,004 New
Renaissance Technologies
17
Renaissance Technologies
New York
$4.6M +$1.74M +256,808 +82%
OFM
18
Omega Fund Management
Massachusetts
$4.45M +$1.69M +250,000 +83%
JGC
19
J. Goldman & Co
New York
$4.3M -$1.73M -255,125 -32%
LOAMU
20
Lombard Odier Asset Management (USA)
New York
$4.23M -$11.3K -1,665 -0.3%
CAM
21
Cormorant Asset Management
Massachusetts
$4.03M +$3.38M +500,000 New
RSCM
22
Rock Springs Capital Management
Maryland
$3.63M +$3.04M +450,000 New
DCM
23
DAFNA Capital Management
California
$3.51M +$2.81M +415,933 +2,181%
Deutsche Bank
24
Deutsche Bank
Germany
$2.93M +$801K +118,419 +48%
Geode Capital Management
25
Geode Capital Management
Massachusetts
$2.26M +$772K +114,142 +69%
1
2 3

CBAY Hedge Fund Activity: Q3 2017 in Review

64 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2017, worth a combined $244M — up 275% from $65M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new CBAY positions and 10 closed out — a net gain of 25 holders — while 22 added to existing stakes and 6 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $15.9M. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $3.74M sold.

  • 64 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2017, up from 39 in Q2 2017.
  • Funds reported $244M of Cymabay Therapeutics stock for Q3 2017, up 275% quarter-over-quarter.
  • 35 funds opened new Cymabay Therapeutics positions in Q3 2017 and 10 closed out, a net change of +25 holders.
  • The largest Cymabay Therapeutics buyer in Q3 2017 was Perceptive Advisors, an estimated $15.9M added.
  • The largest Cymabay Therapeutics seller in Q3 2017 was Ghost Tree Capital, an estimated $3.74M sold.

Based on aggregated 13F filings for Q3 2017.